Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution

Menon S, Davies A, Frentzas S, Hawkins CA, Segelov E, Day D, Markman B

(2022), Cancer Reports, 5(2), e1465

DOI: 10.1002/cnr2.1465

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M

(2022), Eur J Cancer, 165, 97-112

DOI: 10.1016/j.ejca.2022.01.017

18 F-FDG PET/CT features of immune-related adverse events and pitfalls following immunotherapy

Cherk MH, Nadebaum DP, Barber TW, Beech P, Haydon A, Yap KS

(2022), J MED IMAG RADIAT ON, 66(4), 483-94

DOI: 10.1111/1754-9485.13390

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

Niu J, Maurice-Dror C, Lee DH, Kim DW, Nagrial A, Voskoboynik M, Chung HC, Mileham K, Vaishampayan U, Rasco D, Golan T, Bauer TM, Jimeno A, Chung V, Chartash E, Lala M, Chen Q, Healy JA, Ahn MJ

(2022), Ann Oncol, 33(2), 169-80

DOI: 10.1016/j.annonc.2021.11.002

Defining research and infrastructure priorities for cancer survivorship in Australia: a modified Delphi study

Crawford-Williams F, Koczwara B, Chan RJ, Vardy J, Lisy K, Morris J, Iddawela M, Mackay G, Jefford M

(2022), Support Care Cancer, 30(5), 3805-15

DOI: 10.1007/s00520-021-06744-2

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Rottey S, Clarke J, Aung K, Machiels JP, Markman B, Heinhuis KM, Millward M, Lolkema M, Patel SP, de Souza P, Duca M, Curigliano G, Santoro A, Koyama T, Brown M, Vezina H, He C, Chu QS

(2022), Clin Cancer Res, 28(1), 95-105

DOI: 10.1158/1078-0432.CCR-21-1181

Implementing Optimal Care Pathways for Aboriginal and Torres Strait Islander People With Cancer: A Survey of Rural Health Professionals' Self-Rated Learning Needs

Ristevski E, Ludwick T, Leach M, Thompson S, Iddawela M, Pryce M, Wood E, Davidson K, Gell J

(2022), Int J Integr Care, 22(1), 27

DOI: 10.5334/ijic.6028

Impacts of lung cancer multidisciplinary meeting presentation: Drivers and outcomes from a population registry retrospective cohort study

Lin T, Pham J, Paul E, Conron M, Wright G, Ball D, Mitchell P, Atkin N, Brand M, Zalcberg J, Stirling RG

(2022), Lung Cancer, 163, 69-76

DOI: 10.1016/j.lungcan.2021.12.006

Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution

Menon S, Davies A, Frentzas S, Hawkins CA, Segelov E, Day D, Markman B

(2021), Cancer Reports, 5(2), e1465

DOI: 10.1002/cnr2.1465

Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease

McLean LS, Faisal W, Parakh S, Kao SC, Lewis CR, Chin MT, Voskoboynik M, Itchins MJ, Jennens RR, Broad AR, Morris TA, Solomon BJ

(2021), JCO Precis Oncol, 5, 561-8

DOI: 10.1200/PO.20.00464

Improving regional access: Phase 1 teletrials in the era of COVID-19

Gaughran G, Zalcberg J, Hawkins CA, Shackleton M, Voskoboynik M

(2021), ASIA-PAC J CLIN ONCO, 17(4), 416-7

DOI: 10.1111/ajco.13558

A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma

Chowdhury S, Infante JR, Hawkins R, Voss MH, Perini R, Arkenau T, Voskoboynik M, Aimone P, Naeije I, Reising A, McDermott DF

(2021), CLIN GENITOURIN CANC, 19(5), 434-6

DOI: 10.1016/j.clgc.2021.04.007

Personalised cancer care in the era of precision medicine

Koczwara B, Thornton-Benko E, Cohn RJ, Chan RJ, Rhee J, Joske D, Iddawela M, Vardy JL

(2021), Aust J Gen Pract, 50(8), 533-7

DOI: 10.31128/AJGP-04-21-5953

Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma

Wang W, Smith JL, Carlino MS, Burmeister B, Pinkham MB, Fogarty GB, Christie DRH, Estall V, Shackleton M, Clements A, Wolfe R, Thao LTP, Paton EJ, Steel V, Williams NC

(2021), Clinical and Translational Radiation Oncology, 30, 95-9

DOI: 10.1016/j.ctro.2021.08.006

Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies

Tie J, Cohen JD, Lo SN, Wang Y, Li L, Christie M, Lee M, Wong R, Kosmider S, Skinner I, Wong HL, Lee B, Burge ME, Yip D, Karapetis CS, Price TJ, Tebbutt NC, Haydon AM, Ptak J, Schaeffer MJ, Silliman N, Dobbyn L, Popoli M, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P

(2021), Int J Cancer, 148(4), 1014-26

DOI: 10.1002/ijc.33312

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, Sullivan RJ, Chiarion-Sileni V, Nyakas M, Kahler K, Hauschild A, Plummer R, Trojaniello C, Ascierto PA, Zimmer L, Schadendorf D, Allayous C, Lebbe C, Maurichi A, Santinami M, Roy S, Robert C, Lesimple T, Patel S, Versluis JM, Blank CU, Khattak A, Van der Westhuizen A, Carlino MS, Shackleton M, Haydon A

(2021), Brit J Cancer, 124(3), 574-80

DOI: 10.1038/s41416-020-01121-y

Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling

Vergara IA, Mintoff CP, Sandhu S, McIntosh L, Young RJ, Wong SQ, Colebatch A, Cameron DL, Kwon JL, Wolfe R, Peng A, Ellul J, Dou X, Fedele C, Boyle S, Arnau GM, Raleigh J, Hatzimihalis A, Szeto P, Mooi J, Widmer DS, Cheng PF, Amann V, Dummer R, Hayward N, Wilmott J, Scolyer RA, Cho RJ, Bowtell D, Thorne H, Alsop K, Cordner S, Woodford N, Leditschke J, O'Brien P, Dawson SJ, McArthur GA, Mann GJ, Levesque MP, Papenfuss AT, Shackleton M

(2021), Nat Commun, 12(1), 1434

DOI: 10.1038/s41467-021-21576-8

Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi

Robertson SJ, Orme L, Teixeira R, Shamassi M, Newell F, Patch AM, Yeh I, Gard G, Wilmott J, Jackett L, LeBoit P, Fellowes A, MacArthur G, Fox S, Hayward NK, Bastian B, Scolyer R, Waddell N, Penington A, Shackleton M

(2021), JAMA Dermatol, 157(7), 836-41

DOI: 10.1001/jamadermatol.2021.0025

Implementation of patient-reported outcome measures and patient-reported experience measures in melanoma clinical quality registries: a systematic review

Blood Z, Tran A, Caleo L, Saw R, Dieng M, Shackleton M, Soyer HP, Arnold C, Mann GJ, Morton RL

(2021), BMJ Open, 11(2), e040751

DOI: 10.1136/bmjopen-2020-040751

Cancer Diagnoses Following Abnormal Noninvasive Prenatal Testing: A Case Series, Literature Review, and Proposed Management Model

Dow E, Freimund A, Smith K, Hicks RJ, Jurcevic P, Shackleton M, James PA, Fellowes A, Delatycki MB, Fawcett S, Flowers N, Pertile MD, McGillivray G, Mileshkin L

(2021), JCO Precis Oncol, 5, 1001-12

DOI: 10.1200/PO.20.00429

1 2 3 4 5